Andrew S. Wainwright, Author at Thornton Law Firm

New Mesothelioma Drug Fast Tracked by FDA

by Andrew S. Wainwright | May 5, 2021 | Mesothelioma, Mesothelioma and Asbestos, ONCOS-102

The immunotherapy drug ONCOS-102 has been granted Fast Track designation by the Food and Drug Administration (FDA). Fast Track designation speeds up the regulatory review process for the drug. What Is ONCOS-102? ONCOS-102 is an immune activator designed for pleural...

“National Asbestos Awareness Week” established by U.S. Senate

by Andrew S. Wainwright | Apr 1, 2021 | Asbestos, Mesothelioma

The United States Senate has unanimously passed S.Res 145 establishing “National Asbestos Awareness Week” for the 16th time. April 1, 2021 through April 7, 2021 is now devoted...

EPA Must Fully Protect Americans From Asbestos Exposure and Mesothelioma

by Andrew S. Wainwright | Mar 3, 2021 | Asbestos, EPA, Mesothelioma, Mesothelioma and Asbestos

In May of 2020, the Environmental Protection Agency (EPA) published a review of continuing dangers associated with asbestos, pursuant to the the amended Toxic Substances Control Act (TSCA). This risk evaluation was widely criticized by scientists and...

EPA Issues Inadequate Draft Asbestos Risk Evaluation

by Andrew S. Wainwright | Jun 2, 2020 | Asbestos, Cancer, Mesothelioma and Asbestos

The Environmental Protection Agency (EPA) recently issued a Draft Asbestos Risk Evaluation that will keep Americans at severe risk of deadly exposure to asbestos according to the Asbestos Disease Awareness Organization. The ADAO, an independent nonprofit dedicated to...

Masks and Respirators as Protection

by Andrew S. Wainwright | Mar 11, 2020 | Mesothelioma and Asbestos

By: Andrew S. Wainwright As the world confronts the novel coronavirus (and its associated illness, COVID-19), we are becoming more aware of how masks and respirators can, potentially, protect us from airborne contaminants. Individual respiratory protection devices...